KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société KRONOS BIO, INC.
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/04KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/04Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
GL
04/21KRONOS BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/08Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Addition..
GL
04/08Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Addition..
GL
03/08Kronos Bio's Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical ..
GL
03/01Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
GL
02/24KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/24KRONOS BIO : Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financ..
PU
02/24Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Finan..
AQ
02/01Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical..
GL
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
2021Kronos Bio Announces Participation in Upcoming Investor Conferences
AQ
2021KRONOS BIO : Management Change/Compensation - Form 8-K/A
PU
2021KRONOS BIO, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
2021KRONOS BIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Kronos Bio Appoints Roshawn Blunt to Board of Directors
GL
2021Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results - Form ..
PU
2021KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
2021Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
AQ
2021Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Acce..
GL
2021Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Acce..
GL
2021KRONOS BIO ANNOUNCES PARTICIPATION I : Emerging Trends and Therapeutics in Oncology 
GL
2021KRONOS BIO ANNOUNCES PARTICIPATION I : Emerging Trends and Therapeutics in Oncology 
GL
2021KRONOS BIO : to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC..
GL
2021KRONOS BIO : Appoints Marni Kottle as Senior Vice President of Corporate Communications an..
AQ
2021KRONOS BIO : Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conf..
AQ
2021KRONOS BIO : Announced FDA clearance of Investigational New Drug application (IND) for lan..
PU
2021KRONOS BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
2021Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
GL
2021KRONOS BIO : Announces FDA Clearance of Investigational New Drug Application for Lanraplen..
AQ
2021KRONOS BIO : Financial Statements and Exhibits (form 8-K/A)
AQ
2021KRONOS BIO, INC. : Submission of Matters to a Vote of Security Holders, Financial Statemen..
AQ
2021KRONOS BIO : Announces Participation in Upcoming Investor Conferences
AQ
2021KRONOS BIO : to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual ..
PU
2021KRONOS BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021KRONOS BIO : to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual ..
AQ
2021KRONOS BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
2021Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Ann..
GL
2021KRONOS BIO : Reports Recent Business Progress and First Quarter Financial Results and Anno..
PU
2021KRONOS BIO : Announces Participation in Bank of America Securities 2021 Health Care Confer..
AQ
2021Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sust..
GL
2021Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
GL
2021KRONOS BIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors
GL
2021KRONOS BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
2021KRONOS BIO : Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financ..
AQ
2021Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-..
GL
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newl..
GL
2021Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Ora..
GL
2021Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference
GL
2021KRONOS BIO, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021KRONOS BIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
GL
2020KRONOS BIO : Appoints Pasit Phiasivongsa, Ph.D., as Senior Vice President, Pharmaceutical ..
AQ
2020KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2020Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB..
GL
2020KRONOS BIO : Announces Participation in Upcoming Investor Conferences
AQ
2020Kronos Bio Announces Participation in Upcoming Investor Conferences
GL
2020KRONOS BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
2020Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results
GL
2020KRONOS BIO : Reports Recent Business Progress and Third Quarter 2020 Financial Results
AQ
2020KRONOS BIO : Announces Participation in the Jefferies Virtual London Healthcare Conference
AQ
2020Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conferenc..
GL
2020KRONOS BIO : Announces Publication of Preclinical Study Results for Investigational CDK9 I..
AQ
2020Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 ..
GL
2020KRONOS BIO, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8..
AQ
1  2Next
Upcoming event on KRONOS BIO, INC.